View in EDS HTML Full Text PDF Full Text

Masitinib as a neuroprotective agent: a scoping review of preclinical and clinical evidence.

Saved in:
Bibliographic Details
Title: Masitinib as a neuroprotective agent: a scoping review of preclinical and clinical evidence.
Authors: Hamad, Abdullah Ashraf (AUTHOR), Amer, Basma Ehab (AUTHOR), Hawas, Yousef (AUTHOR), Mabrouk, Manar Alaa (AUTHOR), Meshref, Mostafa (AUTHOR)
Source: Neurological Sciences. May2024, Vol. 45 Issue 5, p1861-1873. 13p.
Subjects: Alzheimer's disease, Neuroprotective agents, Amyotrophic lateral sclerosis, Protein-tyrosine kinase inhibitors, Neurodegeneration
Abstract: Objectives: Masitinib, originally developed as a tyrosine kinase inhibitor for cancer treatment, has shown potential neuroprotective effects in various neurological disorders by modulating key pathways implicated in neurodegeneration. This scoping review aimed to summarize the current evidence of masitinib's neuroprotective activities from preclinical to clinical studies. Methods: This scoping review was conducted following the guidelines described by Arksey and O'Malley and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The inclusion criteria covered all original studies reporting on the neuroprotective effects of masitinib, including clinical studies, animal studies, and in vitro studies. Results: A total of 16 studies met the inclusion criteria and were included in the review. These comprised five randomized controlled trials (RCTs), one post-hoc analysis study, one case report, and nine animal studies. The RCTs focused on Alzheimer's disease (two studies), multiple sclerosis (two studies), and amyotrophic lateral sclerosis (one study). Across all included studies, masitinib consistently demonstrated neuroprotective properties. However, the majority of RCTs reported concerns regarding the safety profile of masitinib. Preclinical studies revealed the neuroprotective mechanisms of masitinib, which include inhibition of certain kinases interfering with cell proliferation and survival, reduction of neuroinflammation, and exhibition of antioxidant activity. Conclusion: The current evidence suggests a promising therapeutic benefit of masitinib in neurodegenerative diseases. However, further research is necessary to validate and expand upon these findings, particularly regarding the precise mechanisms through which masitinib exerts its therapeutic effects. Future studies should also focus on addressing the safety concerns associated with masitinib use. [ABSTRACT FROM AUTHOR]
Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 176627746
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Masitinib as a neuroprotective agent: a scoping review of preclinical and clinical evidence.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Hamad%2C+Abdullah+Ashraf%22">Hamad, Abdullah Ashraf</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Amer%2C+Basma+Ehab%22">Amer, Basma Ehab</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hawas%2C+Yousef%22">Hawas, Yousef</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mabrouk%2C+Manar+Alaa%22">Mabrouk, Manar Alaa</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Meshref%2C+Mostafa%22">Meshref, Mostafa</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Neurological+Sciences%22">Neurological Sciences</searchLink>. May2024, Vol. 45 Issue 5, p1861-1873. 13p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Alzheimer's+disease%22">Alzheimer's disease</searchLink><br /><searchLink fieldCode="DE" term="%22Neuroprotective+agents%22">Neuroprotective agents</searchLink><br /><searchLink fieldCode="DE" term="%22Amyotrophic+lateral+sclerosis%22">Amyotrophic lateral sclerosis</searchLink><br /><searchLink fieldCode="DE" term="%22Protein-tyrosine+kinase+inhibitors%22">Protein-tyrosine kinase inhibitors</searchLink><br /><searchLink fieldCode="DE" term="%22Neurodegeneration%22">Neurodegeneration</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Objectives: Masitinib, originally developed as a tyrosine kinase inhibitor for cancer treatment, has shown potential neuroprotective effects in various neurological disorders by modulating key pathways implicated in neurodegeneration. This scoping review aimed to summarize the current evidence of masitinib's neuroprotective activities from preclinical to clinical studies. Methods: This scoping review was conducted following the guidelines described by Arksey and O'Malley and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The inclusion criteria covered all original studies reporting on the neuroprotective effects of masitinib, including clinical studies, animal studies, and in vitro studies. Results: A total of 16 studies met the inclusion criteria and were included in the review. These comprised five randomized controlled trials (RCTs), one post-hoc analysis study, one case report, and nine animal studies. The RCTs focused on Alzheimer's disease (two studies), multiple sclerosis (two studies), and amyotrophic lateral sclerosis (one study). Across all included studies, masitinib consistently demonstrated neuroprotective properties. However, the majority of RCTs reported concerns regarding the safety profile of masitinib. Preclinical studies revealed the neuroprotective mechanisms of masitinib, which include inhibition of certain kinases interfering with cell proliferation and survival, reduction of neuroinflammation, and exhibition of antioxidant activity. Conclusion: The current evidence suggests a promising therapeutic benefit of masitinib in neurodegenerative diseases. However, further research is necessary to validate and expand upon these findings, particularly regarding the precise mechanisms through which masitinib exerts its therapeutic effects. Future studies should also focus on addressing the safety concerns associated with masitinib use. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=176627746
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10072-023-07259-w
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 13
        StartPage: 1861
    Subjects:
      – SubjectFull: Alzheimer's disease
        Type: general
      – SubjectFull: Neuroprotective agents
        Type: general
      – SubjectFull: Amyotrophic lateral sclerosis
        Type: general
      – SubjectFull: Protein-tyrosine kinase inhibitors
        Type: general
      – SubjectFull: Neurodegeneration
        Type: general
    Titles:
      – TitleFull: Masitinib as a neuroprotective agent: a scoping review of preclinical and clinical evidence.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Hamad, Abdullah Ashraf
      – PersonEntity:
          Name:
            NameFull: Amer, Basma Ehab
      – PersonEntity:
          Name:
            NameFull: Hawas, Yousef
      – PersonEntity:
          Name:
            NameFull: Mabrouk, Manar Alaa
      – PersonEntity:
          Name:
            NameFull: Meshref, Mostafa
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: May2024
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 15901874
          Numbering:
            – Type: volume
              Value: 45
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Neurological Sciences
              Type: main
ResultId 1